▶ 調査レポート

尿路感染症治療の世界市場:疾患別、薬物クラス別、病原体別、感染源別

• 英文タイトル:Urinary Tract Infection Treatment Market (Disease: Uncomplicated UTI and Complicated UTI; Drug Class: Quinolones, Beta-lactams, Macrolides, Aminoglycosides, and Others; Pathogen: E. coli, Pseudomonas aeruginosa, Enterococcus spp, K. pneumonia, S. aureus, and Others; Source of Infection: Hospital-acquired UTI and Community-acquired UTI; Gender: Female and Male; Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Urinary Tract Infection Treatment Market (Disease: Uncomplicated UTI and Complicated UTI; Drug Class: Quinolones, Beta-lactams, Macrolides, Aminoglycosides, and Others; Pathogen: E. coli, Pseudomonas aeruginosa, Enterococcus spp, K. pneumonia, S. aureus, and Others; Source of Infection: Hospital-acquired UTI and Community-acquired UTI; Gender: Female and Male; Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027「尿路感染症治療の世界市場:疾患別、薬物クラス別、病原体別、感染源別」(市場規模、市場予測)調査レポートです。• レポートコード:TPM-NV049
• 出版社/出版日:Transparency Market Research / 2019年9月
• レポート形態:英文、PDF、273ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥799,710 (USD5,795)▷ お問い合わせ
  Multi User¥1,213,710 (USD8,795)▷ お問い合わせ
  Global Site License¥1,627,710 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、尿路感染症治療の世界市場について調べ、尿路感染症治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、疾患別(合併症のないUTIおよび合併症のあるUTI)分析、薬物クラス別(キノロン、ベータラクタム、マクロライド、アミノグリコシド、その他)分析、病原体別(大腸菌、緑膿菌、腸球菌、肺炎球菌、黄色ブドウ球菌、その他)分析、感染源別(病院取得型UTIおよびコミュニティ取得型UTI)分析、関連企業情報などをまとめました。
・尿路感染症治療の市場概要
・尿路感染症治療の市場動向
・尿路感染症治療の世界市場規模・予測
・尿路感染症治療市場:疾患別(合併症のないUTIおよび合併症のあるUTI)
・尿路感染症治療市場:薬物クラス別(キノロン、ベータラクタム、マクロライド、アミノグリコシド、その他)
・尿路感染症治療市場:薬物クラス別(キノロン、ベータラクタム、マクロライド、アミノグリコシド、その他)
・尿路感染症治療市場:感染源別(病院取得型UTIおよびコミュニティ取得型UTI)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

Urinary Tract Infection Treatment Market – Scope of the Study

Transparency Market Research (TMR), in its recently published report, determines the key growth opportunities present in the urinary tract infection treatment market for the forecast period of 2019-2027. The comprehensive study traces the significant trends and recent developments encircling the urinary tract infection treatment landscape. In addition to this, it offers actionable insights into the urinary tract infection treatment market by offering a detailed assessment of the key drivers, restraints, threats, and opportunities.

This detailed study provides an analysis of the demand and supply chain, which offers a brief outlook on the balance of the demand-supply chain in the urinary tract infection treatment market. This comprehensive guide discusses the macroeconomic as well as microeconomic parameters that help in understanding the upward growth trajectory of the urinary tract infection treatment market during the forecast period.

The urinary tract infection treatment market size has been evaluated in terms of value (US$ Mn) and volume (‘000 Units). The information included in this exhaustive research report can aid market players of the urinary tract infection treatment market in determining profitable growth prospects for their business advancement.

Urinary Tract Infection Treatment Market – Key Questions Answered

What are the macroeconomic factors that are impeding the growth of the urinary tract infection treatment market?
What is the prevalence of diseases in the urinary tract infection treatment landscape?
How will the urinary tract infection treatment market evolve during the forecast period?
What are the important distribution channels that gauge the potential growth in the urinary tract infection treatment market?
What are the key challenges deterring the growth of the urinary tract infection treatment market?
Urinary Tract Infection Treatment Market – Research Methodology

Transparency Market Research (TMR) follows a robust approach to derive significant insights into the urinary tract infection treatment market. An in-depth study of the growth opportunities for both, market players and stakeholders, was conducted and evaluated in tandem with the market size of urinary tract infection treatment. Crucial segments of the urinary tract infection treatment market are identified, and their market share is taken into consideration to evaluate the size of the urinary tract infection treatment market during the forecast period. In addition to this, the urinary tract infection treatment market segmentation is used as data points, and key insights from primary respondents and opinion leaders of the urinary tract infection treatment market are taken into consideration to estimate the volume and value. Secondary research includes the study of trade journals, press releases, company annual reports, paid resources, and other publications, to obtain distinguished insights.

Urinary Tract Infection Treatment Market – Segmentation

The comprehensive study on the urinary tract infection treatment market provides a comprehensive analysis of the market attractiveness by offering insights into the key segments. The urinary tract infection treatment market has been segregated on the basis of disease, drug class, pathogen, source of infection, gender, distribution channel, and region. The global study highlights a country-wise analysis to lend incisive insights about the healthcare innovations of urinary tract infection treatments.

Each of the segments included in this report help in gaining crucial insights into the urinary tract infection treatment market. The study on the urinary tract infection treatment market offers historical, current, and futuristic trends influencing its growth.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Urinary Tract Infection Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Disease Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.1.1 Rise in prevalence of UTI

4.3.1.2. Increase in number of hospital acquired infection

4.3.1.3. Rise in awareness about women’s health

4.3.1.4. Introduction of new diagnostic test

4.3.1.5. Development of new antibiotics

4.3.2. Restraints

4.3.2.1 Introduction of generic drug

4.3.2.2. Patent Expiry

4.3.3. Opportunities

4.4. Global Urinary Tract Infection Treatment Market Analysis and Forecast, 2017–2027

5. Market Outlook

5.1. Epidemiology Overview of UTI by Key Countries (Prevalence, Incidence, Overall Burden)

5.2. Pipeline Analysis

5.3. Overview of Guidelines for Diagnosis & Treatment of UTI’s

5.4. Reimbursement Scenario

5.5. Overview of Multi-Drug Resistance Pathogen and Infections (Infection Types & Prevalence, Most drug resistant Bacterial Strains)

5.6. Advancements in UTI diagnosis (Rapid Action Tests, New Assays in Anti-microbial susceptibility testing, etc.)

6. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Disease

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Disease, 2017–2027

6.3.1. Uncomplicated UTI

6.3.2. Complicated UTI

6.4. Market Attractiveness, by Disease

7. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Drug Class

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Drug Class, 2017–2027

7.3.1. Quinolones

7.3.2. Beta-lactams

7.3.3. Macrolides

7.3.4. Aminoglycosides

7.3.5. Others

7.4. Market Attractiveness, by Drug Class

8. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Pathogen

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Market Value Forecast, by Pathogen, 2017–2027

8.3.1. E. coli

8.3.2. Pseudomonas aeruginosa

8.3.3. Enterococcus spp

8.3.4. K. pneumoniae

8.3.5. S. aureus

8.3.6. Others

8.4. Market Attractiveness, by Pathogen

9. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Source of Infection

9.1. Introduction & Definition

9.2. Key Findings / Developments

9.3. Market Value Forecast, by Source of Infection, 2017–2027

9.3.1. Hospital Acquired UTI

9.3.2. Community Acquired UTI

9.4. Market Attractiveness, by Source of Infection

10. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Gender

10.1. Introduction & Definition

10.2. Key Findings / Developments

10.3. Market Value Forecast, by Gender, 2017–2027

10.3.1. Female

10.3.2. Male

10.4. Market Attractiveness, by Gender

11. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Distribution Channel

11.1. Introduction & Definition

11.2. Key Findings / Developments

11.3. Market Value Forecast, by Distribution Channel, 2017–2027

11.3.1. Retail Pharmacies

11.3.2. Hospital Pharmacies

11.3.3. Online Pharmacies

11.4. Market Attractiveness, by Distribution Channel

12. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Region

12.1. Key Findings

12.2. Market Value Forecast, by Region

12.2.1. North America

12.2.2. Europe

12.2.3. Asia Pacific

12.2.4. Latin America

12.2.5. Middle East & Africa

12.3. Market Attractiveness, by Country/Region

13. North America Urinary Tract Infection Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Disease, 2017–2027

13.2.1. Uncomplicated UTI

13.2.2. Complicated UTI

13.3. Market Value Forecast, by Drug Class, 2017–2027

13.3.1. Quinolones

13.3.2. Beta-lactams

13.3.3. Macrolides

13.3.4. Aminoglycosides

13.3.5. Others

13.4. Market Value Forecast, by Pathogen, 2017–2027

13.4.1. E. coli

13.4.2. Pseudomonas aeruginosa

13.4.3. Enterococcus spp

13.4.4. K. pneumoniae

13.4.5. S. aureus

13.4.6. Others

13.5. Market Value Forecast, by Source of Infection, 2017–2027

13.5.1. Hospital Acquired UTI

13.5.2. Community Acquired UTI

13.6. Market Value Forecast, by Gender, 2017–2027

13.6.1. Female

13.6.2. Male

13.7. Market Value Forecast, by Distribution Channel, 2017–2027

13.7.1. Retail Pharmacies

13.7.2. Hospital Pharmacies

13.7.3. Online Pharmacies

13.8. Market Value Forecast, by Country, 2017–2027

13.8.1. U.S.

13.8.2. Canada

13.9. Market Attractiveness Analysis

13.9.1. By Disease

13.9.2. By Drug Class

13.9.3. By Pathogen

13.9.4. By Source of Infection

13.9.5. By Gender

13.9.6. By Distribution Channel

13.9.7. By Country

14. Europe Urinary Tract Infection Treatment Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Market Value Forecast, by Disease, 2017–2027

14.2.1. Uncomplicated UTI

14.2.2. Complicated UTI

14.3. Market Value Forecast, by Drug Class, 2017–2027

14.3.1. Quinolones

14.3.2. Beta-lactams

14.3.3. Macrolides

14.3.4. Aminoglycosides

14.3.5. Others

14.4. Market Value Forecast, by Pathogen, 2017–2027

14.4.1. E. coli

14.4.2. Pseudomonas aeruginosa

14.4.3. Enterococcus spp

14.4.4. K. pneumoniae

14.4.5. S. aureus

14.4.6. Others

14.5. Market Value Forecast, by Source of Infection, 2017–2027

14.5.1. Hospital Acquired UTI

14.5.2. Community Acquired UTI

14.6. Market Value Forecast, by Gender, 2017–2027

14.6.1. Female

14.6.2. Male

14.7. Market Value Forecast, by Distribution Channel, 2017–2027

14.7.1. Retail Pharmacies

14.7.2. Hospital Pharmacies

14.7.3. Online Pharmacies

14.8. Market Value Forecast, by Country/Sub-region, 2017–2027

14.8.1. Germany

14.8.2. U.K.

14.8.3. France

14.8.4. Spain

14.8.5. Italy

14.8.6. Rest of Europe

14.9. Market Attractiveness Analysis

14.9.1. By Disease

14.9.2. By Drug Class

14.9.3. By Pathogen

14.9.4. By Source of Infection

14.9.5. By Gender

14.9.6. By Distribution Channel

14.9.7. By Country/Sub-region

15. Asia Pacific Urinary Tract Infection Treatment Market Analysis and Forecast

15.1. Introduction

15.1.1. Key Findings

15.2. Market Value Forecast, by Disease, 2017–2027

15.2.1. Uncomplicated UTI

15.2.2. Complicated UTI

15.3. Market Value Forecast, by Drug Class, 2017–2027

15.3.1. Quinolones

15.3.2. Beta-lactams

15.3.3. Macrolides

15.3.4. Aminoglycosides

15.3.5. Others

15.4. Market Value Forecast, by Pathogen, 2017–2027

15.4.1. E. coli

15.4.2. Pseudomonas aeruginosa

15.4.3. Enterococcus spp

15.4.4. K. pneumoniae

15.4.5. S. aureus

15.4.6. Others

15.5. Market Value Forecast, by Source of Infection, 2017–2027

15.5.1. Hospital Acquired UTI

15.5.2. Community Acquired UTI

15.6. Market Value Forecast, by Gender, 2017–2027

15.6.1. Female

15.6.2. Male

15.7. Market Value Forecast, by Distribution Channel, 2017–2027

15.7.1. Retail Pharmacies

15.7.2. Hospital Pharmacies

15.7.3. Online Pharmacies

15.8. Market Value Forecast, by Country/Sub-region, 2017–2027

15.8.1. China

15.8.2. Japan

15.8.3. India

15.8.4. Australia & New Zealand

15.8.5. Rest of Asia Pacific

15.9. Market Attractiveness Analysis

15.9.1. By Disease

15.9.2. By Drug Class

15.9.3. By Pathogen

15.9.4. By Source of Infection

15.9.5. By Gender

15.9.6. By Distribution Channel

15.9.7. By Country/Sub-region

16. Latin America Urinary Tract Infection Treatment Market Analysis and Forecast

16.1. Introduction

16.1.1. Key Findings

16.2. Market Value Forecast, by Disease, 2017–2027

16.2.1. Uncomplicated UTI

16.2.2. Complicated UTI

16.3. Market Value Forecast, by Drug Class, 2017–2027

16.3.1. Quinolones

16.3.2. Beta-lactams

16.3.3. Macrolides

16.3.4. Aminoglycosides

16.3.5. Others

16.4. Market Value Forecast, by Pathogen, 2017–2027

16.4.1. E. coli

16.4.2. Pseudomonas aeruginosa

16.4.3. Enterococcus spp

16.4.4. K. pneumoniae

16.4.5. S. aureus

16.4.6. Others

16.5. Market Value Forecast, by Source of Infection, 2017–2027

16.5.1. Hospital Acquired UTI

16.5.2. Community Acquired UTI

16.6. Market Value Forecast, by Gender, 2017–2027

16.6.1. Female

16.6.2. Male

16.7. Market Value Forecast, by Distribution Channel, 2017–2027

16.7.1. Retail Pharmacies

16.7.2. Hospital Pharmacies

16.7.3. Online Pharmacies

16.8. Market Value Forecast, by Country/Sub-region, 2017–2027

16.8.1. Brazil

16.8.2. Mexico

16.8.3. Rest of Latin America

16.9. Market Attractiveness Analysis

16.9.1. By Disease

16.9.2. By Drug Class

16.9.3. By Pathogen

16.9.4. By Source of Infection

16.9.5. By Gender

16.9.6. By Distribution Channel

16.9.7. By Country/Sub-region

17. Middle East & Africa Urinary Tract Infection Treatment Market Analysis and Forecast

17.1. Introduction

17.1.1. Key Findings

17.2. Market Value Forecast, by Disease, 2017–2027

17.2.1. Uncomplicated UTI

17.2.2. Complicated UTI

17.3. Market Value Forecast, by Drug Class, 2017–2027

17.3.1. Quinolones

17.3.2. Beta-lactams

17.3.3. Macrolides

17.3.4. Aminoglycosides

17.3.5. Others

17.4. Market Value Forecast, by Pathogen, 2017–2027

17.4.1. E. coli

17.4.2. Pseudomonas aeruginosa

17.4.3. Enterococcus spp

17.4.4. K. pneumoniae

17.4.5. S. aureus

17.4.6. Others

17.5. Market Value Forecast, by Source of Infection, 2017–2027

17.5.1. Hospital Acquired UTI

17.5.2. Community Acquired UTI

17.6. Market Value Forecast, by Gender, 2017–2027

17.6.1. Female

17.6.2. Male

17.7. Market Value Forecast, by Distribution Channel, 2017–2027

17.7.1. Retail Pharmacies

17.7.2. Hospital Pharmacies

17.7.3. Online Pharmacies

17.8. Market Value Forecast, by Country/Sub-region, 2017–2027

17.8.1. GCC Countries

17.8.2. South Africa

17.8.3. Rest of Middle East & Africa

17.9. Market Attractiveness Analysis

17.9.1. By Disease

17.9.2. By Drug Class

17.9.3. By Pathogen

17.9.4. By Source of Infection

17.9.5. By Gender

17.9.6. By Distribution Channel

17.9.7. By Country/Sub-region

18. Competition Landscape

18.1. Market Player – Competition Matrix (By Tier and Size of companies)

18.2. Market Share Analysis/Ranking, by Company, 2018

18.3. Company Profiles

18.3.1. Allergan

18.3.1.1. Company Overview

18.3.1.2. Product Portfolio

18.3.1.3. SWOT Analysis

18.3.1.4. Financial Overview

18.3.1.5. Strategic Overview

18.3.2. Bayer AG

18.3.2.1. Company Overview

18.3.2.2. Product Portfolio

18.3.2.3. SWOT Analysis

18.3.2.4. Financial Overview

18.3.2.5. Strategic Overview

18.3.3. Pfizer, Inc.

18.3.3.1. Company Overview

18.3.3.2. Product Portfolio

18.3.3.3. SWOT Analysis

18.3.3.4. Financial Overview

18.3.3.5. Strategic Overview

18.3.4. GlaxoSmithKline plc

18.3.4.1. Company Overview

18.3.4.2. Product Portfolio

18.3.4.3. SWOT Analysis

18.3.4.4. Financial Overview

18.3.4.5. Strategic Overview

18.3.5. Bristol-Myers Squibb Company

18.3.5.1. Company Overview

18.3.5.2. Product Portfolio

18.3.5.3. SWOT Analysis

18.3.5.4. Financial Overview

18.3.6. Johnson & Johnson (Janssen Global Services, LLC)

18.3.6.1. Company Overview

18.3.6.2. Product Portfolio

18.3.6.3. SWOT Analysis

18.3.6.4. Financial Overview

18.3.6.5. Strategic Overview

18.3.7. LUPIN

18.3.7.1. Company Overview

18.3.7.2. Product Portfolio

18.3.7.3. SWOT Analysis

18.3.7.4. Financial Overview

18.3.7.5. Strategic Overview

18.3.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

18.3.8.1. Company Overview

18.3.8.2. Product Portfolio

18.3.8.3. SWOT Analysis

18.3.8.4. Financial Overview

18.3.8.5. Strategic Overview

18.3.9. Dr. Reddy’s Laboratories Ltd

18.3.9.1. Company Overview

18.3.9.2. Product Portfolio

18.3.9.3. SWOT Analysis

18.3.9.4. Financial Overview

18.3.10. Almirall, S.A

18.3.10.1. Company Overview

18.3.10.2. Product Portfolio

18.3.10.3. SWOT Analysis

18.3.10.4. Financial Overview

18.3.10.5. Strategic Overview

List of Tables

Table 01: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 02: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 03: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 04: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 05: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 06: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 07: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 09: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 10: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 11: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 12: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 13: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 14: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 16: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 17: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 18: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 19: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 20: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 21: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 22: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 23: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 24: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 25: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 26: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 27: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 28: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 29: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 30: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 31: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 32: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 33: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 34: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 35: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 36: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
Table 37: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 38: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
Table 39: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
Table 40: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
Table 41: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 42: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027